Mayo Clinic Laboratory and Pathology Research Roundup: July 11

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.

Featured Abstract

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence

cbd-cancer-pancreatic-tumor-cells-12colWith an overall 5-year survival rate of only 7%, pancreatic ductal adenocarcinoma (PDA) has now eclipsed breast cancer as the third leading cause of cancer death in the United States, and it is predicted to be second by 2030. Despite improvements in surgical and clinical management, the majority of patients with localized PDA who undergo successfully surgical resection succumb to recurrent local or distant metastatic disease. Clinical trials demonstrate single-agent 5-fluorouracil or gemcitabine adjuvant chemotherapy provides overall and disease-free survival benefit, and further adjuvant trials are addressing the efficacy of multi-agent chemotherapy regimens shown to be beneficial in advanced, inoperable PDA. The study was published in Gastroenterology.

Published to PubMed This Week

brentwestra (@brentwestra)


Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.